Trials / Completed
CompletedNCT00118638
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
A Randomized, Double Blind, Active-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 705 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of darbepoetin alfa as 500ug once every 3 weeks to show that the dose and schedule are not inferior to darbepoetin alfa administered as 2.25ug/kg once per week in the treatment of anemia in subjects with non-myeloid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darbepoetin alfa - 2.25 mcg/kg | Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W |
| DRUG | Darbepoetin alfa - 500mcg | Darbepoetin alfa 500mcg Q3W dosing / placebo QW |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2004-12-01
- Completion
- 2005-01-01
- First posted
- 2005-07-12
- Last updated
- 2013-04-29
Source: ClinicalTrials.gov record NCT00118638. Inclusion in this directory is not an endorsement.